The stock's overall trend over the past six months has been sharply negative, declining 22.17% from its price in early October 2025. It has significantly underperformed the broader market, with a relative strength of -19.35% over six months and -20.23% over three months. Short-term performance has been weak, with the stock down 10.68% over the past month and 24.86% over the past three months, far worse than the S&P 500's declines of -5.25% and -4.63%, respectively. The current price of $249.72 is near the bottom of its 52-week range of $239.78 to $360.56, representing a drawdown of approximately 30.7% from its high, indicating the stock is in a deeply oversold position on a price basis.

Revenue growth has been stagnant, with Q4 2025 revenue of $9.20 billion showing minimal year-over-year growth of 0.26%. Profitability has compressed significantly, as the net income margin fell to 1.49% in Q4 2025 from 2.36% in Q4 2024, and quarterly net income dropped to $136.8 million from $216.2 million a year prior. The company's financial health is characterized by high leverage, with a debt-to-equity ratio of 2.22 and a current ratio of 1.17, indicating manageable short-term liquidity but significant long-term debt obligations. Operational efficiency has declined, with Return on Equity (ROE) at 12.36% and Return on Assets (ROA) at 4.22%, both reflecting reduced profitability on capital employed.